“Primary” antiphospholipid syndrome evolving into Waldenstrom’s macroglobulinaemia: a case report

Asherson, Ronald A.; Davidge-Pitts, M.; Wypkema, Emma

doi:10.1007/s10067-005-0144-7

Cited by 8 publications

(4 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A few reports describe patients in whom a diagnosis of a "primary" anti-phospholipid syndrome had evolved into a malignant disease after several years [42].…”

Section: Discussionmentioning

confidence: 99%

Malignancies and Catastrophic Anti-phospholipid Syndrome

Miesbach

2008

Clinic Rev Allerg Immunol

View full text Add to dashboard Cite

The catastrophic anti-phospholipid (Asherson's) syndrome (CAPS) is characterised by the rapid chronological development of fulminant thrombotic complications that predominantly affect small vessels and differs from the anti-phospholipid syndrome in its accelerated systemic involvement leading to multi-organic failure. Malignancy may play a pathogenic role in patients with CAPS, whereas infections are more important as triggering factors in patients without malignancies. CAPS patients with malignancies are generally older than CAPS patients without malignancies; they generally have the worst prognosis of the entire CAPS cohort.

show abstract

“…A few reports describe patients in whom a diagnosis of a "primary" anti-phospholipid syndrome had evolved into a malignant disease after several years [42].…”

Section: Discussionmentioning

confidence: 99%

Malignancies and Catastrophic Anti-phospholipid Syndrome

Miesbach

2008

Clinic Rev Allerg Immunol

View full text Add to dashboard Cite

show abstract

“…20 Nevertheless, there is an evidence that primary APS could evolve into WMG. 21 An association of APS with lymphoma was recorded with the mean time apparently separating the two illnesses ranged from 18 months to 9 years. 22 Our results suggest obligatory detection of paraproteins in sera of patients with AMA M5 and/or aPL, with or without clinical presentations of APS.…”

Section: Discussionmentioning

confidence: 99%

Clinical and serological follow-up of 71 patients with anti-mitochondrial type 5 antibodies

Andrejević¹,

Bonaci-Nikolic²,

Sefik-Bukilica³

et al. 2007

Lupus

View full text Add to dashboard Cite

Antimitochondrial M5 type antibodies (AMA M5) have been described in patients with antiphospholipid syndrome (APS), thrombocytopenia and autoimmune hemolytic anemia. The aim of this study was to describe the clinical and immunological characteristics of a series of patients with AMA M5. We analyzed 71 patients with AMA M5 seen consecutively at our centres during the last 8 years. The clinical and immunological characteristics of diseases expression were compared with 70 consecutive disease control patients without AMA M5. Compared with the control group, AMA M5 positive patients presented higher prevalence of false positive VDRL test (P < 0.001) and thrombocytopenia (P = 0.002) with lower levels of anti-beta2 glycoprotein I antibodies. In AMA M5 patients (56 female, 15 male) a heterogeneous group of disorders were found. Twenty-seven (38%) patients fulfilled the Sapporo criteria for the classification of the APS. Laboratory criteria were met in 55 (77.5%), and clinical criteria in 31 (43.7%) patients. Six patients initially presented with non-criteria features of APS during follow-up period developed APS. Younger patients with AMA M5 should be carefully observed for the development of APS, even in the absence of serological criteria, while elderly must be screened for monoclonal gammopathy and hematological disorders.

show abstract

“…False-positive non-specific syphilis serology (TRUST/venereal disease research laboratory test) can be caused by various diseases, especially autoimmune diseases like antiphospholipid syndrome 1. In addition, plasma cell diseases such as multiple myeloma and macroglobulinaemia can lead to false-positive tests, but titres are usually low, and TP/specific tests (TPPA/TP-ELISA/FTA-ABS) are negative 2.…”

mentioning

confidence: 99%